Titan Biotech Limited (BOM:524717)
India
· Delayed Price · Currency is INR 422.85
-3.20 (-0.75%)
At close: Jun 17, 2025
Titan Biotech Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Cash & Equivalents | 55.58 | 28.4 | 48.64 | 68.14 | 54.51 | Upgrade
|
| Cash & Short-Term Investments | 55.58 | 28.4 | 48.64 | 68.14 | 54.51 | Upgrade
|
| Cash Growth | 95.71% | -41.61% | -28.62% | 25.01% | 197.41% | Upgrade
|
| Accounts Receivable | 188.16 | 186.58 | 210.08 | 163.59 | 181.04 | Upgrade
|
| Receivables | 188.16 | 186.58 | 210.08 | 163.59 | 181.04 | Upgrade
|
| Inventory | 507.23 | 455.71 | 361.7 | 346.8 | 325.38 | Upgrade
|
| Prepaid Expenses | - | 1.87 | 1.23 | - | 1.17 | Upgrade
|
| Other Current Assets | 39.4 | 49.18 | 61.42 | 59.03 | 26.17 | Upgrade
|
| Total Current Assets | 790.38 | 721.74 | 683.06 | 637.56 | 588.26 | Upgrade
|
| Property, Plant & Equipment | 588.46 | 544.7 | 491.04 | 385.15 | 337.85 | Upgrade
|
| Long-Term Investments | 327.7 | 285.48 | 156.69 | 40.31 | - | Upgrade
|
| Other Intangible Assets | 1.22 | 0.95 | 0.85 | 1.05 | 0.92 | Upgrade
|
| Other Long-Term Assets | 39.32 | 12.93 | 13.52 | 16.85 | 80.12 | Upgrade
|
| Total Assets | 1,747 | 1,566 | 1,345 | 1,081 | 1,007 | Upgrade
|
| Accounts Payable | 52.17 | 33.68 | 55.5 | 41.6 | 37.14 | Upgrade
|
| Accrued Expenses | 6.33 | 65.88 | 55.51 | 39.37 | 39.02 | Upgrade
|
| Short-Term Debt | 19.18 | 67.18 | 67 | 64.5 | 82.85 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 11.96 | Upgrade
|
| Current Portion of Leases | 4.6 | 4.38 | 3.81 | 2.9 | 2.5 | Upgrade
|
| Current Income Taxes Payable | - | - | 0.29 | 3.14 | 3.57 | Upgrade
|
| Other Current Liabilities | 95.09 | 20.14 | 21.41 | 17.99 | 15.75 | Upgrade
|
| Total Current Liabilities | 177.36 | 191.25 | 203.51 | 169.49 | 192.8 | Upgrade
|
| Long-Term Debt | 1.84 | 4.53 | 2.99 | 10.81 | 48.55 | Upgrade
|
| Long-Term Leases | 2.35 | 6.94 | 11.32 | 11.09 | 13.98 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 15.21 | 13.72 | 12.07 | 12.76 | 13.89 | Upgrade
|
| Total Liabilities | 213.04 | 231.29 | 246.04 | 218.47 | 282.4 | Upgrade
|
| Common Stock | 82.64 | 82.64 | 82.64 | 82.64 | 82.64 | Upgrade
|
| Additional Paid-In Capital | - | 86.75 | 86.75 | 86.75 | 86.75 | Upgrade
|
| Retained Earnings | - | 1,162 | 928.21 | 692.17 | 517.02 | Upgrade
|
| Comprehensive Income & Other | 1,451 | 3.26 | 1.51 | 0.89 | 1.18 | Upgrade
|
| Total Common Equity | 1,534 | 1,335 | 1,099 | 862.44 | 687.58 | Upgrade
|
| Minority Interest | - | - | - | - | 37.18 | Upgrade
|
| Shareholders' Equity | 1,534 | 1,335 | 1,099 | 862.44 | 724.76 | Upgrade
|
| Total Liabilities & Equity | 1,747 | 1,566 | 1,345 | 1,081 | 1,007 | Upgrade
|
| Total Debt | 27.97 | 83.03 | 85.12 | 89.3 | 159.85 | Upgrade
|
| Net Cash (Debt) | 27.62 | -54.63 | -36.48 | -21.16 | -105.35 | Upgrade
|
| Net Cash Per Share | 3.34 | -6.61 | -4.41 | -2.56 | -12.75 | Upgrade
|
| Filing Date Shares Outstanding | 8.26 | 8.26 | 8.26 | 8.26 | 8.26 | Upgrade
|
| Total Common Shares Outstanding | 8.26 | 8.26 | 8.26 | 8.26 | 8.26 | Upgrade
|
| Working Capital | 613.02 | 530.49 | 479.55 | 468.06 | 395.47 | Upgrade
|
| Book Value Per Share | 185.75 | 161.49 | 133.00 | 104.36 | 83.21 | Upgrade
|
| Tangible Book Value | 1,533 | 1,334 | 1,098 | 861.4 | 686.66 | Upgrade
|
| Tangible Book Value Per Share | 185.60 | 161.38 | 132.90 | 104.24 | 83.09 | Upgrade
|
| Buildings | - | 207.56 | 130.34 | 130.25 | 135.06 | Upgrade
|
| Machinery | - | 391.37 | 281.77 | 254.21 | 236.79 | Upgrade
|
| Construction In Progress | - | 25.32 | 132.94 | 36.34 | 2.7 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.